<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117825">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02037269</url>
  </required_header>
  <id_info>
    <org_study_id>LPM-001</org_study_id>
    <nct_id>NCT02037269</nct_id>
  </id_info>
  <brief_title>CLI Specimen Analyser for Ex-vivo Assessment of Margin and Lymph Node Status in Breast Cancer Surgical Specimens</brief_title>
  <official_title>A Pilot Study to Evaluate Cerenkov Luminescence Imaging for Measuring Margin and Lymph Node Status in Breast Cancer Surgical Specimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lightpoint Medical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lightpoint Medical Limited</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>United Kingdom: National Health Service</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the feasibility of using a Cerenkov Luminescence Imaging (CLI) Specimen
      Analyser for:

        1. the ex-vivo measurement of surgical margin status in breast cancer surgical specimens
           and;

        2. metastatic status of excised lymph nodes.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Tumour margin status of the Wide Local Excision specimen as determined by CLI</measure>
    <time_frame>Intra-operative</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metastatic status of dissected lymph nodes as determined by CLI</measure>
    <time_frame>Intra-operative</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation dosimetry to operating theatre, recovery area and pathology staff</measure>
    <time_frame>Peri-procedural</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of use of CLI Specimen Analyser</measure>
    <time_frame>Intra-operative</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <description>Females with a diagnosis of breast cancer scheduled to have breast conserving surgery +/- sentinel lymph node biopsy or axillary lymph node dissection</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Female patients ≥18 years of age with known breast cancer scheduled for breast-conserving
        surgery (BCS) +/- sentinel lymph node biopsy (SLNB) or axillary lymph node dissection
        (ALND)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females ≥ 50 years of age with a diagnosis of invasive breast cancer or ductal
             carcinoma in-situ (DCIS)

          -  Scheduled for Brest Conserving Surgery (BCS) +/- Sentinel Lymph Node Biopsy (SLNB) or
             Axillary Lymph Node Dissection (ALND)

          -  Females of childbearing age must have a negative pregnancy test (by Beta HCG
             qualitative analysis), must have had a history of a surgical sterilisation, or must
             give history of no menses in past twelve months

        Exclusion Criteria:

          -  Surgery or radiotherapy in the operated breast in the past 2 years

          -  Neoadjuvant systemic therapy

          -  Patients not suitable for BCS

          -  Blood glucose level ≥ 12 mmol/l on the day of surgery

          -  Known hypersensitivity to 18F-FDG

          -  Any patient who is pregnant or lactating
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anand D Purushotham, MBBS FRCS MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vernie Ramalingam</last_name>
      <phone>0044 (0)20 7188 0743</phone>
      <email>Vernie.Ramalingam@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anand D Purushotham, MBBS FRCS MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.lightpointmedical.com/</url>
    <description>Sponsor website</description>
  </link>
  <link>
    <url>http://www.guysandstthomas.nhs.uk/</url>
    <description>Study site web page</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>January 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cerenkov Luminescence CLI  Margin Status</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
